EPGL Medical Invents New Cell Regeneration Technology For Eye
Disease
Technology Holds Promise for People Suffering From Macular
Degeneration and Retinitis Pigmentosa
PR Newswire
IRVINE, Calif., Aug. 7, 2013
IRVINE, Calif., Aug. 7, 2013
/PRNewswire/ -- EP Global Communications, Inc. and EPGL
Medical (the Company), (OTC-PINK: EPGL) announced today that
Company engineers have invented a new device for the purpose of
treating serious eye diseases such as macular degeneration and
retinitis pigmentosa. The technology emits low intensity pulse
ultrasound into the eye for the purpose of regeneration of damaged
cells and to possibly arrest the degeneration of existing healthy
cells within the macula and the entire retina.
"The technology has proven to be very effective in recent
research. We now have the ability to use MEMS to put the
technology into the micro size environment for contact
lenses. This technology will be incorporated into therapeutic
contact lenses which will emit a low, safe dose of the ultrasound
energy into the eye on a regular basis for the purpose of slowing
or arresting the development of macular degeneration, retinitis
pigmentosa and other eye disorders," said David T. Markus, PhD. "We want to pioneer
the area of therapeutic contact lenses and we can see a tremendous
market size and need going into the future for this
technology."
On Monday August 12, 2013 EPGL
Medical will introduce three more advanced technological devices
which is has invented and is currently developing as prototypes and
for FDA clearance in the near future.
Facts on Macular Degeneration
Macular degeneration is the second-highest cause of irreversible
blindness in the world. Macular degeneration is a leading
cause of vision loss in Americans 60 years of age and older.
The number of people living with macular degeneration today is
similar to that of those who have all types of cancer. As many as
11 million people in the United
States have some form of age-related macular degeneration.
This number is expected to double to nearly 22 million by
2050. Macular degeneration is expensive, and will only become
more expensive as the population aged 65 and older increases.
Estimates of the global cost of visual impairment due to
age-related macular degeneration is US$343
billion, including US$255
billion in direct health care costs.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and
marketing company with a world-class team of doctors and scientists
on board. The Company is currently marketing its first FDA
cleared device with several additional "smart" medical devices
under development. The Company is the owner of the cutting
edge technological platform for medical device development called
"Topspin."
RELATED LINKS
http://www.epglmed.com
SOURCE EP Global Communications, Inc.